The week at Retraction Watch featured a praiseworthy retraction by a Nobel laureate, a finding of research misconduct in a much-watched case involving fish and microplastics, and death threats against a journalist reporting on a politician’s plagiarism. Here’s what was happening elsewhere:
Title: Exploration of inhibitory mechanisms of curcumin in lung cancer metastasis using a miRNA- transcription factor-target gene network What Caught Our Attention: The researchers were studying how curcumin, a component of the spice turmeric, can inhibit lung cancer metastases. But upon learning that the primary material had been expired at the time of testing (and … Continue reading Caught Our Notice: What if you find out a paper relied on expired herbal supplement?
Carlo Croce, a cancer researcher who has faced numerous research misconduct allegations, recently accused a former lab member of misconduct. Although an institutional probe did not support that allegation, Croce’s efforts have led to a retraction. In November 2015, Croce and another cancer researcher at Ohio State University (OSU), Ramiro Garzon, contacted PLOS ONE, alleging … Continue reading Carlo Croce, facing misconduct allegations, accuses former colleague of misconduct
Title: Improved Cellular Specificity of Plasmonic Nanobubbles versus Nanoparticles in Heterogeneous Cell Systems What Caught Our Attention: Nanotechnology researcher Dmitri Lapotko, whose work with lasers continues to catch media attention, has earned his fourth retraction. As with the other three, the latest notice mentions an investigation at Rice University, but provides no specific information other than “data falsification” … Continue reading Caught Our Notice: 4th retraction for prominent physicist (with new funding) cites falsification
Although most researchers realize too many are using misidentified cell lines in their work, they may be shocked to see the scope of the problem: Approximately 32,755 articles report on research that relied on misidentified cells, according to a new report in PLoS ONE. And even though more people may be aware of the problem, it … Continue reading Estimate: Nearly 33,000 papers include misidentified cell lines. Experts talk ways to combat growing problem
When Retraction Watch began in 2010, our co-founders Ivan Oransky and Adam Marcus quickly realized they couldn’t keep up with the hundreds of retractions that appeared each year. And the problem has only gotten worse — although we’ve added staff, the number of retractions issued each year has increased dramatically. According to our growing database, just shy of … Continue reading Caught Our Notice: Another retraction for researcher paid $100k to leave uni
The week at Retraction Watch featured the retraction of a paper that had been called “anti-vaccine pseudoscience,” a retraction following threats of violence against an editor, and an editorial board member’s resignation over how a journal handled a case of plagiarism. Here’s what was happening elsewhere:
The week at Retraction Watch featured admissions of fake data from a biotech company whose compound is now in clinical trials, a look at who recycles text, and the apparent demotion of a researcher who had a paper on video games retracted. Here’s what was happening elsewhere:
A biologist who studied the impact of diabetes on the eye inappropriately altered data in five images from three papers, according to a new finding of misconduct issued by the U.S. Office of Research Integrity (ORI). Readers may be familiar with the subject of the findings: Azza El-Remessy, a former tenured associate professor at the … Continue reading ORI finds misconduct in case of biologist paid $100K by university to leave
The week at Retraction Watch featured a look at retractions in China, and an expression of concern for a paper co-authored by a controversial journalist in Australia. Here’s what was happening elsewhere: